Vibrant Therapeutics
Vibrant Therapeutics Raises $61M Series B | Logic-Gated Cancer Immunotherapy
Vibrant Therapeutics Closes $61M for Cancer Immunotherapy
Vibrant Therapeutics, developing logic-gated cancer immunotherapies that activate only in tumor microenvironments, has raised $61 million in Series B funding.
The round was co-led by Pfizer Ventures and Apricot Capital with participation from Bayland Capital and Northern Light Venture Capital.
Key Highlights
- Strategic backing from Pfizer Ventures
- Logic-gated immunotherapy platform
- Tumor microenvironment activation
Company Overview
Vibrant Therapeutics is pioneering logic-gated cancer immunotherapies designed to activate specifically in tumor microenvironments, potentially reducing systemic toxicity while enhancing anti-tumor efficacy.
Company Info
Investors (3)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started